Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

Strategies to Improve Adherence and Clinical Management of Overactive Bladder

Symposium Date: Saturday, May 4, 2013
San Diego Convention Center - San Diego, CA
May 4, 2013

This activity offers CE credit for:

1. Physicians (CME)
2. Nurses (CNE)
3. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Sunday, May 4, 2014
Note: Credit Is No Longer Available

Faculty

Sender Herschorn, BSc, MDCM, FRCSC (Moderator) Professor Division of Urology University of Toronto Head of the Urodynamics Laboratory Sunnybrook Health Sciences Centre Toronto, ON Canada

Christopher Chapple, BSc, MD, FRCS (Urol) FEBU  Consultant Urological Surgeon Royal Hallamshire Hospital Honorary Senior Lecturer of Urology University of Sheffield Visiting Professor of Urology Sheffield Hallam University Chairman of the International Relations Office European Association of Urology Sheffield, UK

Michael B. Chancellor, MD  Professor and Director of Neurourology Oakland University William Beaumont School of Medicine Royal Oak, MI

Statement of Need

High discontinuation rates present a substantial barrier to achieving optimal outcomes in all chronic conditions requiring long-term, consistent pharmacotherapy. Discontinuation rates of 80 percent to 90 percent within the first year of therapy have been reported for overactive bladder (OAB) medications.(1) In order to improve adherence and quality of life for patients with OAB, a proactive and multifaceted approach is needed by clinicians. Frequent and open discussions about side effects or other barriers to pharmacological treatment, or to modify treatment plans and medications can improve adherence. Recommending combined behavioral, psychosocial and pharmacological therapies along with routine discussions about adherence to treatment can improve the dialogue about the overall management of OAB.

This case-based, interactive symposium features a panel that will focus on strategies to empower patients in their care with the goal of improving adherence to recommended treatments for OAB. Faculty will use real-world cases that feature the varied and complex challenges of medication adherence in OAB and collaborate with the audience in the development of key action items and takeaways that can be implemented in clinical practice.

---

1. D'Souza AO, Smith MJ, Miller LA, Doyle J, Ariely R. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm. 2008;14(3):291-301. PMID: 18439051.
2. Thomas L, Culley EJ. Overactive bladder disease: the urge for better therapies. J Manag Care Pharm. 2008;14(4):381-386. PMID: 18500915.

Activity Goal

Make One Change Statement. This educational activity seeks clinicians’ commitment and follow-through in initiating routine discussions regarding patients’ adherence to treatment plans and engaging in a communication dynamic that informs patients about the relationship of treatment adherence to improved quality of life for patients with overactive bladder (OAB).

Learning Objectives

At the end of this CE activity, participants should be able to:

• Identify, discuss, and work with patients to overcome barriers to adherence to agreed upon treatment plans for the management of OAB.
• Initiate a communication dynamic that provides information on current and emerging treatments for OAB and the impact of medication adherence on patients outcomes.

The following learning objectives pertain only to those requesting CNE or CPE credit:

• Review the barriers to adherence in patients with OAB.
• Define which treatment choices can improve adherence in OAB patients.

Financial Support

Supported by an educational grant from Astellas Scientific and Medical Affairs, Inc.

Target Audience

Physicians, physician assistants, nurses, and nurse practitioners with an interest in overactive bladder.

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 2.0 contact hours.

Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST776 (requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Herschorn has disclosed that he has received grant support from Allergan Inc.; Astellas Pharma Inc.; and Pfizer Inc. He is on the speakers bureau for Allergan Inc.; Astellas Pharma Inc.; Eli Lilly and Company; and Pfizer Inc. He serves as a consultant for Allergan Inc.; Astellas Pharma Inc.; Eli Lilly and Company; and Pfizer Inc.

Professor Chapple has disclosed that he has received research support from Allergan Inc.; Astellas Pharma Inc.; Pfizer Inc.; and Recordati S.p.A. He is on the speakers bureau for Allergan Inc.; Astellas Pharma Inc.; Pfizer Inc.; Ranbaxy Laboratories Limited; and Recordati S.p.A. He serves as a consultant for Allergan Inc.; American Medical Systems, Inc.; Astellas Pharma Inc.; Eli Lilly and Company; Ono Pharmaceutical Co., Ltd; Pfizer Inc.; and Recordati S.p.A.

Dr. Chancellor has disclosed that he receive research support from Allergan Inc.; Cook MyoSite, Inc.; Medtronic, Inc. He serves as a consultant for Allergan Inc.; Astellas Pharma Inc.; Cook MyoSite, Inc.; and Lipella Pharmaceuticals Inc.

Nancy Jennings, MSN, MBA, MHA, RNC (content/peer reviewer) has nothing to disclose.

John M. Rodgers, MD (content/peer reviewer) has nothing to disclose.

Robert Kennedy (planning committee) has nothing to disclose.

Joy Bartnett Leffler, MLA, NASW, CSE (planning committee) has nothing to disclose.

Sandra Haas Binford, MAEd (planning committee) has nothing to disclose.

Sharon Tordoff, CCMEP (planning committee) has nothing to disclose.

CME Outfitters, LLC, the faculty, and Astellas Scientific and Medical Affairs, Inc., do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Equal Opportunity Statement: CME Outfitters reserve the right to cancel this program due to unforeseen circumstances. In the unlikely event of such cancellation, CME Outfitters will not be responsible for travel expenses incurred by the participant.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).